Manmeet S Ahluwalia

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8997801/publications.pdf

Version: 2024-02-01

		81900	91884
131	5,786	39	69
papers	citations	h-index	g-index

154	154	154	7692
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Cancer cell heterogeneity & plasticity in glioblastoma and brain tumors. Seminars in Cancer Biology, 2022, 82, 162-175.	9.6	58
2	Sex Differences in Glioblastoma Immunotherapy Response. NeuroMolecular Medicine, 2022, 24, 50-55.	3.4	11
3	Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement. Clinical Cancer Research, 2022, 28, 594-602.	7.0	67
4	Quantitation of terameprocol in human plasma by liquid chromatography-tandem mass spectrometry. Journal of Pharmaceutical and Biomedical Analysis, 2022, 209, 114525.	2.8	0
5	Quality of life following concurrent temozolomide-based chemoradiation therapy or observation in low-grade glioma. Journal of Neuro-Oncology, 2022, 156, 499-507.	2.9	1
6	Radiation necrosis in renal cell carcinoma brain metastases treated with checkpoint inhibitors and radiosurgery: An international multicenter study. Cancer, 2022, 128, 1429-1438.	4.1	21
7	Liquid biopsy in gliomas: A RANO review and proposals for clinical applications. Neuro-Oncology, 2022, 24, 855-871.	1.2	38
8	Surgery, Stereotactic Radiosurgery, and Systemic Therapy in the Management of Operable Brain Metastasis. Neurologic Clinics, 2022, 40, 421-436.	1.8	9
9	Evaluation of the impact of pre-operative stereotactic radiotherapy on the acute changes in histopathologic and immune marker profiles of brain metastases. Scientific Reports, 2022, 12, 4567.	3.3	8
10	Executive summary of American Radium Societyâ€™s appropriate use criteria for the postoperative management of lower grade gliomas. Radiotherapy and Oncology, 2022, 170, 79-88.	0.6	2
11	Hospitalization rates from radiotherapy complications in the United States. Scientific Reports, 2022, 12, 4371.	3.3	5
12	Brain metastases: A Society for Neuro-Oncology (SNO) consensus review on current management and future directions. Neuro-Oncology, 2022, 24, 1613-1646.	1.2	39
13	Cognitive function after concurrent temozolomide-based chemoradiation therapy in low-grade gliomas. Journal of Neuro-Oncology, 2022, 158, 341-348.	2.9	5
14	Sexually dimorphic radiogenomic models identify distinct imaging and biological pathways that are prognostic of overall survival in glioblastoma. Neuro-Oncology, 2021, 23, 251-263.	1.2	24
15	Neutrophil to lymphocyte ratio influences impact of steroids on efficacy of immune checkpoint inhibitors in lung cancer brain metastases. Scientific Reports, 2021, 11, 7490.	3.3	8
16	Integration of Systemic Therapy and Stereotactic Radiosurgery for Brain Metastases. Cancers, 2021, 13, 3682.	3.7	14
17	Impact of MRI timing on tumor volume and anatomic displacement for brain metastases undergoing stereotactic radiosurgery. Neuro-Oncology Practice, 2021, 8, 674-683.	1.6	3
18	Cross-sectional survey of patients, caregivers, and physicians on diagnosis and treatment of brain metastases. Neuro-Oncology Practice, 2021, 8, 662-673.	1.6	6

#	Article	IF	Citations
19	RADI-11. Evaluating the Tissue Effects of Dose-escalated Pre-operative Stereotactic Radiotherapy for Resectable Brain Metastasis. Neuro-Oncology Advances, 2021, 3, iii20-iii20.	0.7	0
20	OTHR-07. Systematic Review and Meta-analysis of Lung Cancer Brain Metastasis and Primary Tumor PD-L1 Expression Discordance. Neuro-Oncology Advances, 2021, 3, iii15-iii16.	0.7	0
21	Impact of KRAS mutation status on the efficacy of immunotherapy in lung cancer brain metastases. Scientific Reports, 2021, 11, 18174.	3.3	15
22	Comparative efficacy of treatments for brain metastases from non-small-cell lung cancer without an EGFR-mutation/ALK-rearrangement: a systematic review and network meta-analysis. World Neurosurgery, 2021, 158, e87-e87.	1.3	2
23	Systematic evaluation and plan quality assessment of the LeksellÂ® gamma knifeÂ® lightning dose optimizer. Medical Dosimetry, 2021, , .	0.9	10
24	Systematic review and meta-analysis of lung cancer brain metastasis and primary tumor receptor expression discordance. Discover Oncology, 2021, 12, 48.	2.1	7
25	An integrated disease-specific graded prognostic assessment scale for melanoma: contributions of KPS, CITV, number of metastases, and BRAF mutation status. Neuro-Oncology Advances, 2021, 3, vdaa152.	0.7	1
26	Systematic review and meta-analysis of PD-L1 expression discordance between primary tumor and lung cancer brain metastasis. Neuro-Oncology Advances, 2021, 3, vdab166.	0.7	5
27	Factors associated with unplanned readmissions and costs following resection of brain metastases in the United States. Scientific Reports, 2021, 11, 22152.	3.3	3
28	Comparative Efficacy of Systemic Agents for Brain Metastases From Non-Small-Cell Lung Cancer With an EGFR Mutation/ALK Rearrangement: A Systematic Review and Network Meta-Analysis. Frontiers in Oncology, 2021, 11, 739765.	2.8	6
29	Impact of EGFR mutation and ALK rearrangement on the outcomes of nonâ€“small cell lung cancer patients with brain metastasis. Neuro-Oncology, 2020, 22, 267-277.	1.2	22
30	Stereotactic radiosurgery with concurrent lapatinib is associated with improved local control for HER2-positive breast cancer brain metastases. Journal of Neurosurgery, 2020, 132, 503-511.	1.6	42
31	Multi-institutional validation of brain metastasis velocity, a recently defined predictor of outcomes following stereotactic radiosurgery. Radiotherapy and Oncology, 2020, 142, 168-174.	0.6	29
32	Epstein-Barr virus-associated primary central nervous system lymphoma in a patient with diffuse cutaneous systemic sclerosis on long-term mycophenolate mofetil. Joint Bone Spine, 2020, 87, 163-166.	1.6	6
33	Medical management of brain metastases. Neuro-Oncology Advances, 2020, 2, vdaa015.	0.7	15
34	Management of brain metastases according to molecular subtypes. Nature Reviews Neurology, 2020, 16, 557-574.	10.1	104
35	Can Tumor Location on Pre-treatment MRI Predict Likelihood of Pseudo-Progression vs. Tumor Recurrence in Glioblastoma?â€”A Feasibility Study. Frontiers in Computational Neuroscience, 2020, 14, 563439.	2.1	1
36	Current approaches to the management of brain metastases. Nature Reviews Clinical Oncology, 2020, 17, 279-299.	27.6	276

#	Article	IF	Citations
37	Radiogenomic-Based Survival Risk Stratification of Tumor Habitat on Gd-T1w MRI Is Associated with Biological Processes in Glioblastoma. Clinical Cancer Research, 2020, 26, 1866-1876.	7.0	67
38	ANG1005, a Brain-Penetrating Peptideâ€“Drug Conjugate, Shows Activity in Patients with Breast Cancer with Leptomeningeal Carcinomatosis and Recurrent Brain Metastases. Clinical Cancer Research, 2020, 26, 2789-2799.	7.0	130
39	Highlights of the 2019 Society for Neuro-Oncology Inaugural Brain Metastases Conference: establishing a dedicated meeting to address an unmet need in the field. Neuro-Oncology Advances, 2020, 2, vdaa036.	0.7	0
40	HER2-targeted therapy prolongs survival in patients with HER2-positive breast cancer and intracranial metastatic disease: a systematic review and meta-analysis. Neuro-Oncology Advances, 2020, 2, vdaa136.	0.7	6
41	Tumor Habitatâ€“derived Radiomic Features at Pretreatment MRI That Are Prognostic for Progression-free Survival in Glioblastoma Are Associated with Key Morphologic Attributes at Histopathologic Examination: A Feasibility Study. Radiology: Artificial Intelligence, 2020, 2, e190168.	5.8	26
42	SATB2 drives glioblastoma growth by recruiting CBP to promote FOXM1 expression in glioma stem cells. EMBO Molecular Medicine, 2020, 12, e12291.	6.9	35
43	Phase II Study of Iniparib with Concurrent Chemoradiation in Patients with Newly Diagnosed Glioblastoma. Clinical Cancer Research, 2019, 25, 73-79.	7.0	12
44	Phase II study of Dovitinib in recurrent glioblastoma. Journal of Neuro-Oncology, 2019, 144, 359-368.	2.9	29
45	The Role of Checkpoint Inhibitors in Glioblastoma. Targeted Oncology, 2019, 14, 375-394.	3.6	30
46	Malignant Transformation of Molecularly Classified Adult Low-Grade Glioma. International Journal of Radiation Oncology Biology Physics, 2019, 105, 1106-1112.	0.8	39
47	Liquid biopsy in central nervous system metastases: a RANO review and proposals for clinical applications. Neuro-Oncology, 2019, 21, 571-584.	1.2	114
48	Quality of life outcomes in patients presenting for evaluation of CNS tumors. Neurology: Clinical Practice, 2019, 9, 32-40.	1.6	2
49	Risk Factors for Progression Among Low-Grade Gliomas After Gross Total Resection and Initial Observation in the Molecular Era. International Journal of Radiation Oncology Biology Physics, 2019, 104, 1099-1105.	0.8	8
50	The impact of sequencing PD-1/PD-L1 inhibitors and stereotactic radiosurgery for patients with brain metastasis. Neuro-Oncology, 2019, 21, 1060-1068.	1.2	76
51	Stereotactic radiosurgery with concurrent HER2-directed therapy is associated with improved objective response for breast cancer brain metastasis. Neuro-Oncology, 2019, 21, 659-668.	1.2	42
52	Current Treatment Options for Breast Cancer Brain Metastases. Current Treatment Options in Oncology, 2019, 20, 19.	3.0	10
53	Upfront Magnetic Resonance Imaging-Guided Stereotactic Laser-Ablation in Newly Diagnosed Glioblastoma: A Multicenter Review of Survival Outcomes Compared to a Matched Cohort of Biopsy-Only Patients. Neurosurgery, 2019, 85, 762-772.	1.1	52
54	Brain metastases. Nature Reviews Disease Primers, 2019, 5, 5.	30.5	579

#	Article	IF	Citations
55	Metronomic capecitabine as an immune modulator in glioblastoma patients reduces myeloid-derived suppressor cells. JCI Insight, 2019, 4, .	5.0	82
56	The Evolving Landscape of Brain Metastasis. Trends in Cancer, 2018, 4, 176-196.	7.4	194
57	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors for Central Nervous System Metastases from Non-Small Cell Lung Cancer. Oncologist, 2018, 23, 1199-1209.	3.7	42
58	Systemic therapy for brain metastases. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2018, 149, 137-153.	1.8	23
59	Impact of pemetrexed on intracranial disease control and radiation necrosis in patients with brain metastases from non-small cell lung cancer receiving stereotactic radiation. Radiotherapy and Oncology, 2018, 126, 511-518.	0.6	18
60	Radiogenomic analysis of hypoxia pathway is predictive of overall survival in Glioblastoma. Scientific Reports, 2018, 8, 7.	3.3	113
61	Risk Factors for Malignant Transformation of Low-Grade Glioma. International Journal of Radiation Oncology Biology Physics, 2018, 100, 965-971.	0.8	64
62	Clinical trial design for local therapies for brain metastases: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group. Lancet Oncology, The, 2018, 19, e33-e42.	10.7	42
63	Clinical trial design for systemic agents in patients with brain metastases from solid tumours: a guideline by the Response Assessment in Neuro-Oncology Brain Metastases working group. Lancet Oncology, The, 2018, 19, e20-e32.	10.7	87
64	Correlation Between the Residual Tumor Volume, Extent of Tumor Resection, and O6-Methylguanine DNA Methyltransferase Status in Patients with Glioblastoma. World Neurosurgery, 2018, 116, e147-e161.	1.3	8
65	Phase I Trial of Radiosurgery Dose Escalation Plus Bevacizumab in Patients With Recurrent/Progressive Glioblastoma. Neurosurgery, 2018, 83, 385-392.	1.1	20
66	Shape Features of the Lesion Habitat to Differentiate Brain Tumor Progression from Pseudoprogression on Routine Multiparametric MRI: A Multisite Study. American Journal of Neuroradiology, 2018, 39, 2187-2193.	2.4	61
67	Novel Systemic Treatments for Brain Metastases From Lung Cancer. Current Treatment Options in Neurology, 2018, 20, 48.	1.8	6
68	Whole-Brain Radiotherapy for Brain Metastases: Evolution or Revolution?. Journal of Clinical Oncology, 2018, 36, 483-491.	1.6	151
69	Management of Brain Metastases in the New Era of Checkpoint Inhibition. Current Neurology and Neuroscience Reports, 2018, 18, 70.	4.2	25
70	Expression of LC3B and FIP200/Atg17 in brain metastases of breast cancer. Journal of Neuro-Oncology, 2018, 140, 237-248.	2.9	7
71	Recent advances in managing brain metastasis. F1000Research, 2018, 7, 1772.	1.6	63
72	Management of Brain Metastases in Tyrosine Kinase Inhibitorâ€“NaÃ¯ve Epidermal Growth Factor Receptorâ€“Mutant Nonâ€“Small-Cell Lung Cancer: A Retrospective Multi-Institutional Analysis. Journal of Clinical Oncology, 2017, 35, 1070-1077.	1.6	372

#	Article	IF	Citations
73	The impact of tumor biology on survival and response to radiation therapy among patients with nonâ€“small cell lung cancer brain metastases. Practical Radiation Oncology, 2017, 7, e263-e273.	2.1	20
74	Overall survival and the response to radiotherapy among molecular subtypes of breast cancer brain metastases treated with targeted therapies. Cancer, 2017, 123, 2283-2293.	4.1	51
75	The risk of radiation necrosis following stereotactic radiosurgery with concurrent systemic therapies. Journal of Neuro-Oncology, 2017, 133, 357-368.	2.9	102
76	The Prognostic Role of Tumor Volume in the Outcome of Patients with Single Brain Metastasis After Stereotactic Radiosurgery. World Neurosurgery, 2017, 104, 229-238.	1.3	15
77	Targeted Treatment of Brain Metastases. Current Neurology and Neuroscience Reports, 2017, 17, 37.	4.2	28
78	Treatment of Glioblastoma in Older Adults. Current Oncology Reports, 2017, 19, 81.	4.0	45
79	Prediction of new brain metastases after radiosurgery: validation and analysis of performance of a multi-institutional nomogram. Journal of Neuro-Oncology, 2017, 135, 403-411.	2.9	30
80	Macropinocytosis of Bevacizumab by Glioblastoma Cells in the Perivascular Niche Affects their Survival. Clinical Cancer Research, 2017, 23, 7059-7071.	7.0	26
81	Cumulative Intracranial Tumor Volume and Number of Brain Metastasis as Predictors of Developing New Lesions After Stereotactic Radiosurgery for Brain Metastasis. World Neurosurgery, 2017, 106, 666-675.	1.3	12
82	First followâ€up radiographic response is one of the predictors of local tumor progression and radiation necrosis after stereotactic radiosurgery for brain metastases. Cancer Medicine, 2017, 6, 2076-2086.	2.8	16
83	Correlation of higher levels of soluble TNF-R1 with a shorter survival, independent of age, in recurrent glioblastoma. Journal of Neuro-Oncology, 2017, 131, 449-458.	2.9	8
84	Intracranial and Systemic Response to Alectinib in a Patient with RET-KIF5B Oncogenic Fusion. Journal of Thoracic Oncology, 2017, 12, e98-e99.	1.1	7
85	Targeted therapy of brain metastases: latest evidence and clinical implications. Therapeutic Advances in Medical Oncology, 2017, 9, 781-796.	3.2	46
86	CMET-01. EFFICACY AND OUTCOME OF ANTI-PD1 THERAPY IN PATIENTS WITH LUNG CANCER BRAIN METASTASIS. Neuro-Oncology, 2017, 19, vi39-vi39.	1.2	1
87	An Excellent Clinical Outcome with Stereotactic Radiosurgery in a Geriatric Patient with Multiple and Recurrent Brain Metastases. Cureus, 2017, 9, e1979.	0.5	0
88	Targeted Therapy in Brain Metastases: Ready for Primetime?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, e123-e130.	3.8	35
89	Immune Checkpoint Inhibitors in Brain Metastases: From Biology to Treatment. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 35, e116-e122.	3.8	65
90	BMET-16. REVISED GRADED PROGNOSTIC ASSESSMENT FOR NON-SMALL CELL LUNG CANCER (NSCLC) BRAIN METASTASES (BM) IN THE ERA OF MOLECULAR PROFILING. Neuro-Oncology, 2016, 18, vi29-vi29.	1.2	0

#	Article	IF	Citations
91	Clinical study of a survivin long peptide vaccine (SurVaxM) in patients with recurrent malignant glioma. Cancer Immunology, Immunotherapy, 2016, 65, 1339-1352.	4.2	105
92	Association Between Radiation Necrosis and Tumor Biology After Stereotactic Radiosurgery for Brain Metastasis. International Journal of Radiation Oncology Biology Physics, 2016, 96, 1060-1069.	0.8	109
93	A cure is possible: a study of 10-year survivors of brain metastases. Journal of Neuro-Oncology, 2016, 129, 545-555.	2.9	25
94	Intracranial hemorrhage in setting of glioblastoma with venous thromboembolism. Neuro-Oncology Practice, 2016, 3, 87-96.	1.6	26
95	Treatment of Large Brain Metastases With Stereotactic Radiosurgery. Technology in Cancer Research and Treatment, 2016, 15, 186-195.	1.9	20
96	Management of Brain Metastasis in Patients With Pulmonary Neuroendocrine Carcinomas. Technology in Cancer Research and Treatment, 2016, 15, 566-572.	1.9	9
97	Principles of pharmacotherapy. Handbook of Clinical Neurology / Edited By P J Vinken and G W Bruyn, 2016, 134, 149-162.	1.8	1
98	Recurrent venous thromboembolism in glioblastoma. Thrombosis Research, 2016, 137, 184-188.	1.7	45
99	The intersection of cancer, cancer stem cells, and the immune system: therapeutic opportunities. Neuro-Oncology, 2016, 18, 153-159.	1.2	86
100	Immune Checkpoint Inhibitors in Brain Metastases: From Biology to Treatment. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 36, e116-e122.	3.8	28
101	Targeted Therapy in Brain Metastases: Ready for Primetime?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2016, 36, e123-e130.	3.8	13
102	Targeted and Immunotherapeutic Approaches in Brain Metastases. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , 67-74.	3.8	16
103	Whole-Brain Radiotherapy and Stereotactic Radiosurgery in Brain Metastases: What Is the Evidence?. American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting, 2015, , e99-e104.	3.8	14
104	Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma. Neuro-Oncology, 2015, 17, 1275-1283.	1.2	61
105	Efficacy and patient-reported outcomes with dose-intense temozolomide in patients with newly diagnosed pure and mixed anaplastic oligodendroglioma: a phase II multicenter study. Journal of Neuro-Oncology, 2015, 122, 111-119.	2.9	22
106	Differential Connexin Function Enhances Self-Renewal in Glioblastoma. Cell Reports, 2015, 11, 1031-1042.	6.4	100
107	Phase II trial of triple tyrosine kinase receptor inhibitor nintedanib in recurrent high-grade gliomas. Journal of Neuro-Oncology, 2015, 121, 297-302.	2.9	42
108	Bevacizumab in high-grade gliomas: past, present, and future. Expert Review of Anticancer Therapy, 2015, 15, 387-397.	2.4	18

#	Article	IF	Citations
109	A phase I study of cediranib in combination with cilengitide in patients with recurrent glioblastoma. Neuro-Oncology, 2015, 17, 1386-1392.	1.2	50
110	Growth Factor Receptor Fusions Predict Therapeutic Sensitivity. Clinical Cancer Research, 2015, 21, 3105-3107.	7.0	0
111	Phase II trial of sunitinib as adjuvant therapy after stereotactic radiosurgery in patients with 1â€“3 newly diagnosed brain metastases. Journal of Neuro-Oncology, 2015, 124, 485-491.	2.9	23
112	Response assessment after stereotactic body radiotherapy for spinal metastasis: a report from the SPIne response assessment in Neuro-Oncology (SPINO) group. Lancet Oncology, The, 2015, 16, e595-e603.	10.7	170
113	Prognostic scores for brain metastasis patients: use in clinical practice and trial design. Chinese Clinical Oncology, 2015, 4, 18.	1.2	47
114	Phase II trial of patupilone in patients with brain metastases from breast cancer. Neuro-Oncology, 2014, 16, 579-583.	1.2	23
115	Medical therapy of gliomas. Journal of Neuro-Oncology, 2014, 119, 503-512.	2.9	15
116	Brain metastasis and treatment. F1000prime Reports, 2014, 6, 114.	5.9	44
117	Recurrent or refractory primary central nervous lymphoma: therapeutic considerations. Expert Review of Anticancer Therapy, 2013, 13, 1109-1119.	2.4	12
118	Challenges With the Diagnosis and Treatment of Cerebral Radiation Necrosis. International Journal of Radiation Oncology Biology Physics, 2013, 87, 449-457.	0.8	251
119	Chemotherapy for Brain Tumors. , 2012, , 94-104.		0
120	Therapeutic targeting of VEGF in the treatment of glioblastoma. Expert Opinion on Therapeutic Targets, 2012, 16, 973-984.	3.4	35
121	Molecular targeted therapy in recurrent glioblastoma: current challenges and future directions. Expert Opinion on Investigational Drugs, 2012, 21, 1247-1266.	4.1	50
122	Flow cytometry as a diagnostic tool in lymphomatous or leukemic meningitis. Cancer, 2012, 118, 1747-1753.	4.1	43
123	Primary Central Nervous System Lymphoma in Elderly Patients: Clinical Outcomes and Prognosis. Blood, 2012, 120, 5083-5083.	1.4	0
124	Antiangiogenic therapy for patients with glioblastoma: current challenges in imaging and future directions. Expert Review of Anticancer Therapy, 2011, 11, 653-656.	2.4	38
125	Phase II trial of ritonavir/lopinavir in patients with progressive or recurrent high-grade gliomas. Journal of Neuro-Oncology, 2011, 102, 317-321.	2.9	35
126	Role of tyrosine kinase inhibitors in the management of high-grade gliomas. Expert Review of Anticancer Therapy, 2011, 11, 1739-1748.	2.4	4

#	Article	IF	Citations
127	Primary Central Nervous System Lymphoma. Current Treatment Options in Neurology, 2010, 12, 347-359.	1.8	15
128	Progress on Antiangiogenic Therapy for Patients with Malignant Glioma. Journal of Oncology, 2010, 2010, 1-14.	1.3	45
129	Targeting SRC in glioblastoma tumors and brain metastases: Rationale and preclinical studies. Cancer Letters, 2010, 298, 139-149.	7.2	104
130	Thalidomide in Multiple Myeloma - A Community Hospital Experience.. Blood, 2005, 106, 5140-5140.	1.4	1
131	Successful Use of Recombinant Factor VIIa in Reversal of Life Threatening Bleeding Caused by Coagulopathy.. Blood, 2005, 106, 4077-4077.	1.4	0